Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest urinary retention Stories

2011-09-22 15:47:00

DENVER, Sept. 22, 2011 /PRNewswire-iReach/ -- Do you know your Prostate Health Risk? Men over the age of 40 need to know if they are at increased risk. Perform a 100% Private & Secure Prostate Symptoms Self-Assessment for free right now and find out. (Photo: http://photos.prnewswire.com/prnh/20110922/CG73782) In an attempt to educate men over 40 of their increased risk of an enlarged prostate and possibly BPH, URINOZINC® is sharing its easy to use Prostate...

2011-08-24 12:46:00

SILVER SPRING, Md., Aug. 24, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Botox (onabotulinumtoxinA) injection to treat urinary incontinence in people with neurologic conditions such as spinal cord injury and multiple sclerosis who have overactivity of the bladder. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Uninhibited urinary bladder contractions in people with some neurological conditions can lead to an inability to store urine....

2011-05-17 14:31:00

DEERFIELD, Ill., May 17, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas Pharma US"), U.S. subsidiary of Astellas Pharma Inc. (Tokyo: TSE: 4503, "the Company"), today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms - urinary incontinence (leakage of urine) and frequency of micturition...

2011-03-22 09:36:00

TOKYO, March 22, 2011 /PRNewswire-FirstCall/ -- Astellas Pharma Inc.(TSE:4503,"Astellas") ( http://www.astellas.com/en/corporate/) today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition[1,2]. These data were presented for the first time this week at...

2010-10-06 17:22:52

When compared with placebo and other drugs, long-term use of finasteride improves urinary tract symptoms associated with benign prostatic hyperplasia, and reduces disease progression. This conclusion comes from combining the findings of 23 randomized clinical trials that evaluated almost 21,000 men, and is published this month in The Cochrane Library. Finasteride is frequently given to men who have lower urinary tract symptoms (LUTS) such as frequent voiding at night (nocturia), incomplete...

2010-08-11 15:00:00

RESEARCH TRIANGLE PARK, N.C. and ALISO VIEJO, Calif., Aug. 11 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced today that a U.S. Food and Drug Administration (FDA) advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of ezogabine as adjunctive treatment for adults with partial-onset seizures. After a review of the safety data, including urinary retention,...

2010-03-26 08:53:23

Patients who have a history of bladder control problems may benefit from an implantable device that uses electrical pulses to alter abnormal communication between bladder nerves and the brain, said a urologist at Baylor College of Medicine. "Patients with these bladder issues often suffer from significant embarrassment and a low quality of life," said Dr. Christopher Smith, associate professor in the Scott Department of Urology at BCM. "This has been a life-changing treatment for some...

2010-03-02 12:56:28

DALLAS -- Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center. The findings, published in a recent issue of the journal European Urology, compared treatments for three groups of study participants with enlarged prostates over four years. The study, which included more than 4,800 men, is one of the first to compare single...

2010-03-02 05:30:00

MINNEAPOLIS, March 2 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that at the February 23-27, 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), in St. Petersburg, FL, nine presentations were made on Uroplasty's Urgent® PC Neuromodulation System and...

2009-12-16 09:00:00

BOTHELL, Wash., Dec. 16 /PRNewswire/ -- Verathon®, maker of BladderScan® bladder volume instruments is pleased to announce that portable bladder volume ultrasound is now included in the new 2009 CDC guidelines for the Prevention of Catheter-Associated Urinary Tract Infections (CA-UTIs). The new CDC guidelines, introduced in early November 2009, replace the previous guidelines which date back to 1981. The guidelines are located on the Web at:...


Latest urinary retention Reference Libraries

Cystoscopy
2013-01-18 11:39:08

Cystoscopy is a medical procedure to explore the bladder with a cytoscope, a small camera with magnification. The bladder is accessed by the cytoscope through the urethra. This procedure is used as a diagnostic tool for the medical provider. Reasons for Procedure There are several complaints from patients that would make this procedure a consideration of the medical provider. Patients that present with chronic urinary tract infections, decrease in bladder control, abnormal urine...

More Articles (1 articles) »